{"brief_title": "Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis", "brief_summary": "The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).", "condition": "Multiple Sclerosis, Relapsing-Remitting", "intervention_type": "Drug", "intervention_name": "Placebo", "description": "Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.", "arm_group_label": "Group 2", "other_name": "Tysabri", "criteria": "Inclusion Criteria: - Diagnosis of MS as defined by McDonald et al., criteria # 1-4 - Between the ages of 18 and 55, inclusive - Baseline EDSS score between 0.0 and 5.0, inclusive - Have been treated with GA for at least the 12 months prior to randomization Exclusion Criteria: - Primary progressive, secondary progressive or progressive relapsing MS - MS relapse has occurred within the 50 days prior to randomization - A clinically significant infectious illness - History of, or abnormal lab result indicative of significant disease that would preclude the administration of a recombinant humanized antibody immunomodulating agent or GA for 20 weeks.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "55 Years", "healthy_volunteers": "No", "id": "NCT00097760.xml"}